thalidomide has been researched along with Choroid Neovascularization in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lyzogubov, V | 1 |
| Dasso, M | 1 |
| Bora, N | 1 |
| Bora, PS | 1 |
| Dong, LF | 1 |
| Yao, J | 1 |
| Wang, XQ | 1 |
| Shan, K | 1 |
| Yang, H | 1 |
| Yan, B | 1 |
| Jiang, Q | 1 |
| Ciardella, AP | 1 |
| Donsoff, IM | 1 |
| Guyer, DR | 1 |
| Adamis, A | 1 |
| Yannuzzi, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization[NCT00555594] | Phase 2/Phase 3 | 18 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Choroid Neovascularization
| Article | Year |
|---|---|
Antiangiogenesis agents.
Topics: Angiogenesis Inhibitors; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Interferon | 2002 |
2 other studies available for thalidomide and Choroid Neovascularization
| Article | Year |
|---|---|
Role of thalidomide, senicapoc, and sodium butyrate in choroidal neovascularization.
Topics: Acetamides; Angiogenesis Inhibitors; Animals; Butyric Acid; Cell Line; Cell Proliferation; Choroidal | 2020 |
Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Ch | 2015 |